Gouty Arthritis Market- Industry Growth, Size, Share & Trends

 

Gouty Arthritis is a form of arthritis that causes inflammation, typically in one joint, which begins suddenly. Gouty arthritis is due to the deposition of needle-shaped crystals of uric acid in a joint. The primary outward indications of gouty arthritis include severe pain, swelling, and redness in joints, often in the big toe.

By Gouty Arthritis Market report Increasing prevalence of gout with rising alcohol consumption is expected to drive growth of the global gouty arthritis market. In line with the Centers for Disease Control and Prevention (CDC), from 2013-2015 around 54.4 million adults in the U.S. have some kind of arthritis, gout, rheumatoid arthritis, or fibromyalgia. In line with the Arthritis Foundation, 8 million people in the U.S. suffer with gout arthritis every year. In line with the same source, high intake of sugary or alcoholic drinks is one of many major risk factors for gout arthritis. Alcohol is really a major supply of purine, which produces uric acid. High degrees of uric acids in the body can result in the forming of crystals of uric acid, eventually resulting in gout. Hence, such factors are expected to drugs market is expected to drive growth of the global gouty arthritis market. Furthermore, increasing adoption of biologics and increasing R&D activities in regenerative medicines is expected to propel the global gouty arthritis market growth in the near future.

Side-effects connected with therapeutics drugs and high indirect costs of gout therapeutics are expected to hamper the global gouty arthritis market growth in the near future. Besides, not enough awareness one of the medical fraternity regarding effective treatment of the condition, typically in emerging economies is expected to restrain growth of the Gouty Arthritis Market. Among regions, North America is expected to witness significant growth in the global gouty arthritis market. That is owing to high prevalence of gouty arthritis in the U.S. In line with the clinical guidelines for gout published in Annals of Internal Medicine, in 2017, around 3.9% of U.S. adults aged 20 years and above reported gout one or more times in a lifetime. Furthermore, Asia Pacific is expected to join up a strong growth rate, owing to rising amount of patients struggling with chronic diseases such as for instance cardiovascular disease over the region.

Key companies involved in the global gouty arthritis market are Lannett Company, Inc., Teijin Pharma Ltd, Boehringer Ingelheim, Takeda Pharmaceutical Company Ltd, GlaxoSmithKline plc, ROMEG Therapeutics, LLC, Horizon Therapeutics plc, Regeneron Pharmaceuticals, Mylan NV, Merck& Co. Inc., and Novartis International AG.

For example, in February 2019, ROMEG Therapeutics, LLC received the U.S. Food and Drug Administration (FDA) approval for its GLOPERBA (colchicine) Oral Solution, 0.6 mg/5 mL for prophylaxis of gout flares in adults.